Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in ...

Researchers are engineering a new class of miniature antibodies, called intrabodies, that can operate inside living cells to break down the toxic proteins behind Alzheimer’s disease and motor neurone ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

A genetic variant carried by at least one-fifth of the population may do far more than raise the odds of developing Alzheimer ...

Internal medicine doctor diagnosed with Alzheimer's at 57 shares how monoclonal antibody treatment restored his cognitive ...

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...

What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...

New treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and motor neuron disease (MND) could be unlocked thanks to microscopic medicines developed by researchers at the University ...

After decades of slow progress in understanding and developing effective treatments for Alzheimer’s disease, scientists are ...

Rural Americans face higher Alzheimer's risk but often lack access to specialists and early diagnostic tools, prompting calls ...

Hormone therapy is widely used to treat menopausal symptoms such as hot flashes and night sweats. But scientists have long ...

HHS Secretary Robert F. Kennedy Jr. appointed Michelle Branham as chair of the federal Advisory Council on Alzheimer’s ...